paper_id,claim,figure_id,title,caption,local_image_path,url
PMC11476771,"Safety analyses were summarized descriptively.Multiple-dose administration
Study design
A multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",PMC11476771_figure_1,Fig. 1.,"Multiple-Dose Study Design in Part A. IV, intravenous; TIW, three times a week",./data/PMC11476771/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/d18ba5542b86/12882_2024_3790_Fig1_HTML.jpg
PMC11476771,"Mean duration of ESRD and of chronic HD was similar across groups.PK analyses
Single-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",PMC11476771_figure_2,Fig. 2.,"Mean Difelikefalin Concentrations in NDD Subjects with Varying Degrees of (a, b) Renal Impairment and (c) HD Subjects*. *No PK assessments were performed between 48 and 92 h. Concentrations from day 1 to day 8 (linear scale) in the PK population. For the calculation of means, individual concentration values that were below the limit of quantitation (BLQ of 0.100 ng/mL) were treated as zero. IV bolus was administered after each dialysis session; dialysis occurred on days 1, 3, 5, and 8. PK, pharmacokinetic; SD, standard deviation",./data/PMC11476771/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/e837492a6ca1/12882_2024_3790_Fig3_HTML.jpg
PMC11476771,Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.,PMC11476771_figure_2,Fig. 2.,"Mean Difelikefalin Concentrations in NDD Subjects with Varying Degrees of (a, b) Renal Impairment and (c) HD Subjects*. *No PK assessments were performed between 48 and 92 h. Concentrations from day 1 to day 8 (linear scale) in the PK population. For the calculation of means, individual concentration values that were below the limit of quantitation (BLQ of 0.100 ng/mL) were treated as zero. IV bolus was administered after each dialysis session; dialysis occurred on days 1, 3, 5, and 8. PK, pharmacokinetic; SD, standard deviation",./data/PMC11476771/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/e837492a6ca1/12882_2024_3790_Fig3_HTML.jpg
PMC11476771,"Multiple-dose administration
Study design
A multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",PMC11476771_figure_1,Fig. 1.,"Multiple-Dose Study Design in Part A. IV, intravenous; TIW, three times a week",./data/PMC11476771/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/d18ba5542b86/12882_2024_3790_Fig1_HTML.jpg
PMC11476771,"Study design
A multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",PMC11476771_figure_1,Fig. 1.,"Multiple-Dose Study Design in Part A. IV, intravenous; TIW, three times a week",./data/PMC11476771/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/d18ba5542b86/12882_2024_3790_Fig1_HTML.jpg
PMC11476771,"A multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",PMC11476771_figure_1,Fig. 1.,"Multiple-Dose Study Design in Part A. IV, intravenous; TIW, three times a week",./data/PMC11476771/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/d18ba5542b86/12882_2024_3790_Fig1_HTML.jpg
PMC11476771,"PK analyses
Single-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",PMC11476771_figure_2,Fig. 2.,"Mean Difelikefalin Concentrations in NDD Subjects with Varying Degrees of (a, b) Renal Impairment and (c) HD Subjects*. *No PK assessments were performed between 48 and 92 h. Concentrations from day 1 to day 8 (linear scale) in the PK population. For the calculation of means, individual concentration values that were below the limit of quantitation (BLQ of 0.100 ng/mL) were treated as zero. IV bolus was administered after each dialysis session; dialysis occurred on days 1, 3, 5, and 8. PK, pharmacokinetic; SD, standard deviation",./data/PMC11476771/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/e837492a6ca1/12882_2024_3790_Fig3_HTML.jpg
PMC11476771,"Single-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",PMC11476771_figure_2,Fig. 2.,"Mean Difelikefalin Concentrations in NDD Subjects with Varying Degrees of (a, b) Renal Impairment and (c) HD Subjects*. *No PK assessments were performed between 48 and 92 h. Concentrations from day 1 to day 8 (linear scale) in the PK population. For the calculation of means, individual concentration values that were below the limit of quantitation (BLQ of 0.100 ng/mL) were treated as zero. IV bolus was administered after each dialysis session; dialysis occurred on days 1, 3, 5, and 8. PK, pharmacokinetic; SD, standard deviation",./data/PMC11476771/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e93/11476771/e837492a6ca1/12882_2024_3790_Fig3_HTML.jpg
